EUCTR2005-002536-94-DE进行中（未招募）不适用
A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. RE-MEDY - RE-MEDY
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Objectively confirmed symptomatic uni- or bilateral DVT of the leg involving proximal veins or PE, treated with approved anticoagulant therapy, or with study drug taken during participation in trial 1160.53 or trial 1160.46, for 3 to 12 months at the time of screening, in patients considered at increased risk of recurrent VTE [proximal veins are: trifurcation area, popliteal, superficial femoral, deep femoral, common femoral and iliac vein]
- •2. Male or female, being 18 years of age or older
- •3. Written informed consent for study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Symptomatic DVT or PE at screening
- •2. Patients with primary PE with suspected origin other that leg limbs (e.g. upper limbs, right heart).
- •3. Actual or anticipated use of vena cava filter
- •4. Interruption of anticoagulant therapy for 2 or more weeks during the 3 - 12 months of treatment for the prior VTE.
- •5. Patients who in the investigator’s opinion should not be treated with warfarin
- •6. Allergy to warfarin or dabigatran, or to one of the excipients included in these medications
- •7. Patients who in the investigator’s judgement are perceived as having an excessive risk of bleeding, for example because of:
- •- Hemorrhagic disorder or bleeding diathesis
- •- Trauma or major surgery within the last month or as long as an excessive risk of bleeding persists after these events, or planned major surgery
- •- Any of the following intracranial pathologies: neoplasm, arteriovenous malformation or aneurysm
- •- History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra-articular bleeding
- •- Gastrointestinal haemorrhage within the past 3 months.
- •- Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 days
- •- Treatment with thrombolytic agents within 14 days before enrolment
- •- Anticipated need of quinidine or other restricted medication during the treatment period (see Section 4.2.2)
- •- Known thrombocytopenia (platelet count < 100•109•L-1)
- •8. Known anaemia (haemoglobin < 100 g•L-1)
- •9. Need of anticoagulant treatment for disorders other than VTE
- •10. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrolment (investigator’s judgement), acute bacterial endocarditis or history of myocardial infarction within the last 3 months
- •11. Elevated AST or ALT > 2x ULN based on the local lab results obtained at screening and prior to randomisation (or central screening lab if available on time)
- •12. Liver disease expected to have any potential impact on survival (e.g. acute hepatitis, or possibly active hepatitis B, hepatitis C or cirrhosis, but not Gilbert’s syndrome or hepatitis A with complete recovery)
- •13. Patients who have developed transaminase elevations upon exposure to ximelagatran
- •14. Severe renal impairment (estimated creatinine clearance = 30 ml/min)
- •15. Women who are pregnant, nursing or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study (NOTE: A negative pregnancy test must be obtained for any woman of childbearing potential prior to entry into the study)
- •16. Participation in another clinical trial with an investigational drug during the last 30 days, except for the RE-COVER or RE-COVER 2 trials, or previous participation in this study
- •17. Patients considered unsuitable for inclusion by the investigator, e.g. because considered unreliable to comply with the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator would not allow safe participation in the study (e.g., drug addiction, alcohol abuse)
- •18. In case of anticipated study related diagnostic procedures requiring contrast medium
- •(e.g. contrast venography or pulmonary angiography):
- •Elevated serum creatinine, which in the investigator’s opinion contraindicates these examinations
- •Known allergy to radio opaque contrast media or iodine, which in the investigator’
研究者
相似试验
进行中（未招募）
1 期
A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. RE-MEDY - RE-MEDYConfirmed Venous Thromboembolism (VTE) i.e. uni or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins and/or pulmonay embolism (PE) - treated with anticoagulant for 3 to 6 monthsEUCTR2005-002536-94-SKBoehringer Ingelheim Pharma Ges mbH2,000
进行中（未招募）
1 期
A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. RE-MEDY - RE-MEDYConfirmed Venous Thromboembolism (VTE) i.e. uni or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins and/or pulmonay embolism (PE) - treated with anticoagulant for 3 to 6 monthsEUCTR2005-002536-94-FIBoehringer Ingelheim Finland Ky2,000
进行中（未招募）
1 期
A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. RE-MEDY - RE-MEDYConfirmed Venous Thromboembolism (VTE) i.e. uni or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins and/or pulmonay embolism (PE) - treated with anticoagulant for 3 to 12 monthsEUCTR2005-002536-94-GRBoehringer Ingelheim Ellas AE2,000
进行中（未招募）
不适用
A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. RE-MEDY - RE-MEDYEUCTR2005-002536-94-BGBoehringer Ingelheim Austria GmbH2,000
进行中（未招募）
不适用
A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. RE-MEDY - RE-MEDYConfirmed Venous Thromboembolism (VTE) i.e. uni or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins and/or pulmonay embolism (PE) - treated with anticoagulant for 3 to 6 monthsEUCTR2005-002536-94-DKBoehringer Ingelheim France2,000